secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2026-07-16T12:35:13+00:00
Accession:  0001104659-26-084095
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences preannounces record Q2 revenue of ~$261M, CFO steps down
----------------------------------------------------------------------------

- Preliminary Q2 2026 WAKIX net revenue ~$261M, record quarter, up 30% YoY and 21% QoQ.
- Reaffirms full-year 2026 net revenue guidance of $1.0B-$1.04B.
- CFO Glenn Reicin steps down effective July 16, 2026 to pursue other opportunities.
- Stephen Mollichella, SVP and Controller, appointed Interim Principal Financial Officer.
- Full Q2 results to be reported on August 4, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/0001104659-26-084095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465926084095/hrmy-20260716x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-084095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer